ClinicalTrials.gg
RecruitingNCT07286032Updated Oct 1, 2026

A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)

A Phase 3 interventional study of Hetrombopag Olamine and Hetrombopag Olamine; Hetrombopag Olamine Placebo in Patients With Chemotherapy-Induced Thrombocytopenia, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 51 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 1, 2026First sites in 10 new countriesSite recruiting status changed+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 177 studies in Thrombocytopenia with a site in United States — 18 open to participants now, 21 under way, 3 of them phase 3. Thrombocytopenia · United States.

Planned enrollment
24th of 136
150 · median 35
Started
2026
with 5 others
Phase 3
26 of 177
2 open now
Primary completion
2028-12
later than 13 of 19 live
Registered
173rd of 177
by date

Among the 177 studies in Thrombocytopenia with a site in United States, this one is the 24th largest by planned enrollment of the 136 interventional ones that give a count, is one of 6 that started in 2026, is one of 26 in phase 3, reaches primary completion later than 13 of the 19 other live ones, and was the 173rd registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

18 of the 177 studies in Thrombocytopenia with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Thrombocytopenia with a site in United States, or all of them as a file.
02

Study summary

The ExCIT study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.

03

Conditions studied

  • Patients With Chemotherapy-Induced Thrombocytopenia

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥ 18 years at screening.
  2. or cytologically confirmed solid tumor (e.g., non-small-cell lung carcinoma [NSCLC], breast, ovarian, bladder, pancreatic, gastrointestinal, or colon/colorectal cancer).
  3. Receiving platinum- and/or gemcitabine-containing chemotherapy regimens on 14- or 21-day treatment cycles.
  4. count \< 85 x 109/L at enrollment.
  5. For Part B, experiencing a chemotherapy delay of ≥ 7 days due to CIT.
  6. At least 2 scheduled chemotherapy cycles of the same treatment regimen as was used prior to enrollment.
  7. performance status (ECOG PS) 0-2.
  8. ≥6 months.
  9. Signed ICF for voluntary participation in the study and good compliance.

Exclusion criteria

Exclusion Criteria:

  1. WHO Grade ≥ 2 bleeding within 14 days prior to screening.
  2. Hematopoietic diseases other than CIT (e.g., primary immune thrombocytopenia).
  3. Hematologic .
  4. Thrombocytopenia caused by reasons other than chemotherapy, including but not limited to chronic liver disease, hypersplenism, infection, and hemorrhage, within 6 months prior to Study Day 1.
  5. Untreated ; or with .
  6. Conditions that require emergent treatment (e.g., superior vena cava syndrome, spinal cord compression).
  7. Severe cardiovascular disorders or interventions within 6 months.
  8. Have arterial/venous thrombosis with anticoagulation not tolerated for at least 6 weeks.
  9. Known bleeding disorders, dysfunction.
  10. Severe haemorrhage during screening (e.g., gastrointestinal or intracranial hemorrhage) within 28 days prior to enrolment.
  11. Previous treatment with thrombopoietin receptor agonists (TPO-RAs) within 14 days prior to enrolment.
  12. Platelet transfusion within 72 hours prior to enrollment.
  13. Acute or uncontrolled \&C infection.
  14. (HIV) infection.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Part A: Hetrombopag Olamine

    Drug: Hetrombopag Olamine

  • Experimental
    Part B: Hetrombopag Olamine vs Hetrombopag Olamine Placebo

    Drug: Hetrombopag Olamine; Hetrombopag Olamine Placebo

Interventions

  • For Part A, all participants would receive hetrombopag treatment.

  • DrugHetrombopag Olamine; Hetrombopag Olamine Placebo

    For Part B, participants would be randomized to receive hetrombopag treatment or matching placebo, respectively.

06

What researchers measure

Primary outcomes

  1. Part A: Cmax of hetrombopag in non-Asian participants with CIT, around 6 months.

    Time frame: around 6 months.

  2. Part A: AUC0-tauof hetrombopag in non-Asian participants with CIT, around 6 months.

    Time frame: around 6 months.

  3. Part A: Cmin of hetrombopag in non-Asian participants with CIT, around 6 months.

    Time frame: around 6 months.

  4. Part B: A platelet count of ≥100×109/L within 14 days after initiating the investigational product treatment, around 3 years.

    Time frame: around 3 years.

  5. Part B: No use of any rescue therapy for thrombocytopenia during the treatment period from the initiation of investigational product treatment until the end of the primary treatment period, around 3 years.

    Time frame: around 3 years.

  6. Part B: Complete two consecutive on-study chemotherapy cycles (Cycle 1 and Cycle 2) without thrombocytopenia-induced modification of any myelosuppressive agent, around 3 years.

    Time frame: around 3 years.

Secondary outcomes

  1. Proportion of participants achieving platelet count ≥100×109/L without the use of rescue therapy within 14 days after initiating the investigational product treatment, around 3 years.

    Time frame: around 3 years.

  2. Platelet count nadir from Cycle 1 Day 1 until the primary treatment period, around 3 years.

    Time frame: around 3 years.

  3. Proportion of participants free from serious bleeding events, during the treatment period from the initiation of IP treatment until the primary treatment period, around 3 years.

    Time frame: around 3 years.

  4. Proportion of participants with neutropenia during the treatment period from the initiation of IP treatment until the primary treatment period, around 3 years.

    Time frame: around 3 years.

  5. Number of Adverse Events/Serious Adverse Events, safety lab parameters, vital signs, etc within study period, around 3 years.

    Time frame: around 3 years.

07

Study locations

17 of 51 sites recruiting
  • Starling Oncology
    Long Beach, California 90805, United States
    Not yet recruiting
    • Omkar Marathe · Contact
    • Omkar Marathe · Principal investigator
  • Cancer and Blood Specialty Clinic
    Los Alamitos, California 90254, United States
    Recruiting
    • Arati Chand · Principal investigator
  • UCLA
    Los Angeles, California 90095, United States
    Recruiting
    • Wanxing Chai-Ho · Contact
    • Wanxing Chai-Ho · Principal investigator
  • Clermont Oncology Center
    Clermont, Florida 34711, United States
    Recruiting
    • Gopal Kunta · Contact
    • Kunta Kunta · Principal investigator
  • Oncology & Hematology Associates of West Broward
    Coral Springs, Florida 33065, United States
    Recruiting
    • Sumit Sawhney · Principal investigator
  • Starling Oncology / Oncology Institute of Hope & Innovation
    Miami, Florida 33141, United States
    Not yet recruiting
    • David Luis Sumoza · Contact
    • David Luis Sumoza · Principal investigator
  • Mid-Florida Hematology & Oncology Centers, P.A.
    Orange City, Florida 32763, United States
    Recruiting
    • Santosh Nair · Contact
    • Santosh Nair · Principal investigator
  • Springfield Clinic
    Springfield, Illinois 62702, United States
    Recruiting
    • Preet Singh · Principal investigator
  • University of Iowa
    Iowa City, Iowa 52242, United States
    Recruiting
    • Naomi Fei · Contact
    • Naomi Fei · Principal investigator
  • Hattiesburg Clinic Hematology/Oncology
    Hattiesburg, Mississippi 39401, United States
    Not yet recruiting
    • John Hrom · Contact
    • John Hrom · Principal investigator
  • Cancer Partners of Nebraska
    Lincoln, Nebraska 68516, United States
    Recruiting
    • Irfan Vaziri · Contact
    • Irfan Vaziri · Principal investigator
  • Morristown Medical Center
    Morristown, New Jersey 07039, United States
    Not yet recruiting
    • Se young Han · Principal investigator
  • MSK Cancer Center
    New York, New York 10065, United States
    Not yet recruiting
    • Jodi Mones · Contact
    • Jodi Mones · Principal investigator
  • New York Cancer and Blood Specialists One Oncology
    Shirley, New York 11967, United States
    Not yet recruiting
    • Richard Zuniga · Principal investigator
  • ARENSIA Exploratory Medicine at "MBAL Sveta Sofia"
    Sofia, Bulgaria
    Recruiting
    • Marchela Koleva, Dr. · Contact
    • Marchela Koleva, Dr. · Principal investigator
  • UMHAT "Sv. Ivan Rilski", EAD
    Sofia, Bulgaria
    Not yet recruiting
    • Robev Bozhil · Contact
    • Robev Bozhil · Principal investigator
  • Hong Kong United Oncology Centre
    Hong Kong, Hong Kong 000000, China
    Not yet recruiting
    • Yu Chung Li · Contact
    • Yu Chung Li · Principal investigator
  • The Chinese University of Hong Kong
    Hong Kong, Hong Kong 000000, China
    Not yet recruiting
    • Herbert Long · Contact
    • Herbert Long · Principal investigator
  • The University of Hong Kong
    Hong Kong, Hong Kong 000000, China
    Not yet recruiting
    • Rina Hui · Contact
    • Rina Hui · Principal investigator
  • Gustave Roussy Cancer Campus
    Clémont, France
    Recruiting
    • Florian Scotté · Contact
    • Florian Scotté · Principal investigator
  • Centre Hospitalier Lyon Sud
    Lyon, France
    Not yet recruiting
    • Freyer Gilles · Contact
    • Freyer Gilles · Principal investigator
  • Groupe Hospitalier Pitie-Salpetriere
    Paris, France
    Not yet recruiting
    • Abbar Baptiste · Contact
    • Abbar Baptiste · Principal investigator
  • Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari
    Bari, Italy
    Not yet recruiting
    • Guida Michele · Contact
    • Guida Michele · Principal investigator
  • Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda)
    Milan, Italy
    Not yet recruiting
    • Sartore-Bianchi Andrea · Contact
    • Sartore-Bianchi Andrea · Principal investigator
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, Italy
    Not yet recruiting
    • Antonuzzo Andrea · Contact
    • Antonuzzo Andrea · Principal investigator
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, Italy
    Not yet recruiting
    • Secondino Simona · Contact
    • Secondino Simona · Principal investigator
  • Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. ks. B. Markiewicza
    Brzozów, Poland
    Not yet recruiting
    • Joanna Kiszka · Contact
    • Joanna Kiszka · Principal investigator
  • Uniwersytecki Szpital Kliniczny w Poznaniu, Klinika Onkologii
    Poznan, Poland
    Not yet recruiting
    • Rodryg Ramlau · Contact
    • Rodryg Ramlau · Principal investigator
  • Institutul Oncologic Bucuresti Prof Dr. Al. Trestioreanu with SC Arensia Exploratory Medicine
    Bucharest, Romania
    Recruiting
    • Laurentia Nicoleta Gales · Contact
    • Laurentia Nicoleta Gales · Principal investigator
  • Institute of Oncology "Ioan Chiricuta" Cluj-Napoca, Arensia Exploratory Medicine
    Cluj-Napoca, Romania
    Recruiting
    • Tudor Eliade Ciuleanu · Contact
    • Tudor Eliade Ciuleanu · Principal investigator
  • Centrul de Oncologie Sfantul Nectarie Craiova
    Craiova, Romania
    Not yet recruiting
    • Michael Schenker · Contact
    • Michael Schenker · Principal investigator
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
    Recruiting
    • Eun Hee Jung · Contact
    • Eun Hee Jung · Principal investigator
  • Seoul National University Hospital
    Seoul, 03080, South Korea
    Recruiting
    • Do-Youn Oh · Contact
    • Do-Youn Oh · Principal investigator
  • Asan Medical Center
    Seoul, 05505, South Korea
    Not yet recruiting
    • Kyu-pyo Kim · Contact
    • Kyu-pyo Kim · Principal investigator
  • Pratia ES Sirius Barcelona
    Barcelona, Spain
    Recruiting
    • Santiago Viteri Ramirez · Contact
    • Santiago Viteri Ramirez · Principal investigator
  • Hospital Universitario Reina Sofía Córdoba
    Córdoba, Spain
    Not yet recruiting
    • Elisabeth Inga Saavedra · Contact
    • Elisabeth Inga Saavedra · Principal investigator
  • Hospital Universitari Arnau de Vilanova
    Lleida, Spain
    Not yet recruiting
    • Salud Salvia Antonieta · Contact
    • Salud Salvia Antonieta · Principal investigator
  • Hospital Universitario HM Madrid Sanchinarro
    Madrid, Spain
    Not yet recruiting
    • Huertas Mondejar Helena · Contact
    • Huertas Mondejar Helena · Principal investigator
  • Hospital Universitario Ramón y Cajal
    Madrid, Spain
    Not yet recruiting
    • Belén de Frutos González · Contact
    • Belén de Frutos González · Principal investigator
  • Pratia ES Hospital Universitario de Torrejon
    Madrid, Spain
    Recruiting
    • Sara Custodio Cabello · Contact
    • Sara Custodio Cabello · Principal investigator
  • Complejo Hospitalario Universitario de Orense
    Ourense, Spain
    Not yet recruiting
    • Salgado Fernandez Mercedes · Contact
    • Salgado Fernandez Mercedes · Principal investigator
  • Hospital Universitario General de Cataluña
    Sant Cugat del Vallès, Spain
    Not yet recruiting
    • Xabier González Farré · Contact
    • Xabier González Farré · Principal investigator
  • Ankara Univ Cebeci Hospital Medical Oncology
    Mamak, Ankara, Turkey (Türkiye)
    Not yet recruiting
    • Yuksel Urun · Contact
    • Yuksel Urun · Principal investigator
  • Istanbul Univ. Cerrahpasa Medical Faculty Hosp.
    Fatih, Istanbul, Turkey (Türkiye)
    Not yet recruiting
    • Mustafa Ozguroglu · Contact
    • Mustafa Ozguroglu · Principal investigator
  • Goztepe Prof. Dr. Suleyman Yalcin City Hospital
    Kadıköy, Istanbul, Turkey (Türkiye)
    Not yet recruiting
    • Mahmut Gümüş · Contact
    • Mahmut Gümüş · Principal investigator
  • Marmara University Pendik Training and Research Hospital
    Pendik, Istanbul, Turkey (Türkiye)
    Not yet recruiting
    • Osman Kostek · Contact
    • Osman Kostek · Principal investigator
  • I.E.U. Medicalpoint Izmir Hospital
    Izmir, Turkey (Türkiye)
    Not yet recruiting
    • Cagatay Arslan · Contact
    • Cagatay Arslan · Principal investigator
  • Pamukkale University Hospital
    Kınıklı, Turkey (Türkiye)
    Not yet recruiting
    • Yuksel Urun · Contact
    • Yuksel Urun · Principal investigator
  • Sakarya Univ. Training & Research Hosp. Oncology
    Sakarya, Turkey (Türkiye)
    Not yet recruiting
    • Ilhan Hacibekiroglu · Contact
    • Ilhan Hacibekiroglu · Principal investigator
  • Ankara Oncology TRH Clinical Research Center
    Yenimahalle, Turkey (Türkiye)
    Not yet recruiting
    • Ayse Ocak Duran · Contact
    • Ayse Ocak Duran · Principal investigator
  • ARENSIA Exploratory Medicine LLC
    Kyiv, Ukraine
    Recruiting
    • Myroslava Doronina · Contact
    • Myroslava Doronina · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.

Of 29 phase 3 interventional studies under Thrombocytopenia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 45. This study's planned 32 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 16, 2025
StartActual
Apr 16, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Jun 2029
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
45 sites added, 1 site removed — first sites in Bulgaria, China, France, Italy, Poland and 5 more
All 10 countries

Bulgaria, China, France, Italy, Poland, Romania, South Korea, Spain, Turkey (Türkiye), Ukraine

. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Cancer and Blood Specialty Clinic · Los Alamitos, United StatesNot yet recruiting→Recruiting
  • Oncology & Hematology Associates of West Broward · Coral Springs, United StatesNot yet recruiting→Recruiting
  • Springfield Clinic · Springfield, United StatesNot yet recruiting→Recruiting
Show 45 added (8 United States, 8 Spain, 8 Turkey (Türkiye), 4 Italy, 3 China, 3 France, 3 Romania, 3 South Korea, 2 Bulgaria, 2 Poland, 1 Ukraine)
  • Starling Oncology · Long Beach, United States
  • UCLA · Los Angeles, United States
  • Clermont Oncology Center · Clermont, United States
  • Starling Oncology / Oncology Institute of Hope & Innovation · Miami, United States
  • University of Iowa · Iowa City, United States
  • Hattiesburg Clinic Hematology/Oncology · Hattiesburg, United States
  • Cancer Partners of Nebraska · Lincoln, United States
  • MSK Cancer Center · New York, United States
  • ARENSIA Exploratory Medicine at "MBAL Sveta Sofia" · Sofia, Bulgaria
  • UMHAT "Sv. Ivan Rilski", EAD · Sofia, Bulgaria
  • Hong Kong United Oncology Centre · Hong Kong, China
  • The Chinese University of Hong Kong · Hong Kong, China
  • The University of Hong Kong · Hong Kong, China
  • Gustave Roussy Cancer Campus · Clémont, France
  • Centre Hospitalier Lyon Sud · Lyon, France
  • Groupe Hospitalier Pitie-Salpetriere · Paris, France
  • Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari · Bari, Italy
  • Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda) · Milan, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori · Milan, Italy
  • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
  • Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. ks. B. Markiewicza · Brzozów, Poland
  • Uniwersytecki Szpital Kliniczny w Poznaniu, Klinika Onkologii · Poznan, Poland
  • Institutul Oncologic Bucuresti Prof Dr. Al. Trestioreanu with SC Arensia Exploratory Medicine · Bucharest, Romania
  • Institute of Oncology "Ioan Chiricuta" Cluj-Napoca, Arensia Exploratory Medicine · Cluj-Napoca, Romania
  • Centrul de Oncologie Sfantul Nectarie Craiova · Craiova, Romania
  • Seoul National University Bundang Hospital · Seongnam-si, South Korea
  • Seoul National University Hospital · Seoul, South Korea
  • Asan Medical Center · Seoul, South Korea
  • Pratia ES Sirius Barcelona · Barcelona, Spain
  • Hospital Universitario Reina Sofía Córdoba · Córdoba, Spain
  • …and 15 more on the registry record
Show 1 removed
  • AdventHealth Hematology and Oncology Denver Cypress Hematology and Oncology · Denver, United States
Oct 1, 2026
Eligibility
2 inclusion criteria edited, 3 added; 1 exclusion criterion edited, 4 added, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedMale or female gender, age ≥ 18 years at screening.
  • EditedReceiving platinum- and/or gemcitabine-containing chemotherapy regimens on 14- or 21-day treatment cycles.
  • AddedPlatelet count < 85 x 109/L at enrollment.
  • AddedFor Part B, experiencing a chemotherapy delay of ≥ 7 days due to CIT.
  • AddedAt least 2 scheduled chemotherapy cycles of the same treatment regimen as was used prior to enrollment.
Exclusion criteria
  • AddedWHO Grade ≥ 2 bleeding within 14 days prior to screening.
  • EditedHave arterial/venous thrombosis withinwith anticoagulation not tolerated for at least 6 monthsweeks.
  • RemovedSevere haemorrhage during screening
  • AddedSevere haemorrhage during screening (e.g., gastrointestinal or intracranial hemorrhage) within 28 days prior to enrolment.
  • AddedPrevious treatment with thrombopoietin receptor agonists (TPO-RAs) within 14 days prior to enrolment.
  • AddedPlatelet transfusion within 72 hours prior to enrollment.
Oct 1, 2026
Interventions
Changed Hetrombopag Olamine ;Hetrombopag Olamine Placebo→Hetrombopag Olamine; Hetrombopag Olamine Placebo. Arm changed Part B:Hetrombopag Olamine vs Hetrombopag Olamine Placebo→Part B: Hetrombopag Olamine vs Hetrombopag Olamine Placebo
Oct 1, 2026
Primary outcomes
5 edited
What changed in the outcomes
  • EditedPart A: AUC0-tauof hetrombopag in non-Asian participants with CIT, around 6 months.Time frame: around 6 months → around 6 months.
  • EditedPart A: Cmin of hetrombopag in non-Asian participants with CIT, around 6 months.Time frame: around 6 months → around 6 months.
  • EditedPart B: A platelet count of ≥100×109/L within 14 days after initiating the investigational product treatment, around 3 years.Time frame: around 3 years → around 3 years.
  • EditedPart B: No use of any rescue therapy for thrombocytopenia during the treatment period from the initiation of investigational product treatment until Cycle 2 Day 21the end of the primary treatment period, around 3 years.Time frame: around 3 years.
  • EditedPart B: Complete two consecutive on-study chemotherapy cycles (Cycle 1 and Cycle 2) without thrombocytopenia-induced modification of any myelosuppressive agent, around 3 years;.Time frame: around 3 years; → around 3 years.
Oct 1, 2026
Secondary outcomes
4 edited
What changed in the outcomes
  • EditedProportion of participants achieving platelet count ≥100×109/L without the use of rescue therapy within 14 days after initiating the investigational product treatment, around 3 years;.Time frame: around 3 years; → around 3 years.
  • EditedplateletPlatelet count nadir from Cycle 1 Day 1 until Cycle 2 Day 21the primary treatment period, around 3 years;.Time frame: around 3 years; → around 3 years.
  • EditedProportion of participants free from serious bleeding events, during the treatment period from the initiation of IP treatment until C2D21the primary treatment period, around 3 years;.Time frame: around 3 years; → around 3 years.
  • EditedProportion of participants with neutropenia during the treatment period from the initiation of IP treatment until Cycle 2 Day 21the primary treatment period, around 3 years.Time frame: around 3 years.
Oct 1, 2026
Contact
Study contact changed: j•••@hengrui.com · •••2973→b•••@hengrui.com · •••3900; added j•••@hengrui.com · •••2973. See the current contact
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Mid-Florida Hematology & Oncology Centers, P.A. · Orange City, United StatesContact added (no phone or email listed)
Oct 1, 2026
Title
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    45 sites added, 1 site removed — first sites in Bulgaria, China, France, Italy, Poland and 5 more
    All 10 countries

    Bulgaria, China, France, Italy, Poland, Romania, South Korea, Spain, Turkey (Türkiye), Ukraine

    . 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Cancer and Blood Specialty Clinic · Los Alamitos, United StatesNot yet recruiting→Recruiting
    • Oncology & Hematology Associates of West Broward · Coral Springs, United StatesNot yet recruiting→Recruiting
    • Springfield Clinic · Springfield, United StatesNot yet recruiting→Recruiting
    Show 45 added (8 United States, 8 Spain, 8 Turkey (Türkiye), 4 Italy, 3 China, 3 France, 3 Romania, 3 South Korea, 2 Bulgaria, 2 Poland, 1 Ukraine)
    • Starling Oncology · Long Beach, United States
    • UCLA · Los Angeles, United States
    • Clermont Oncology Center · Clermont, United States
    • Starling Oncology / Oncology Institute of Hope & Innovation · Miami, United States
    • University of Iowa · Iowa City, United States
    • Hattiesburg Clinic Hematology/Oncology · Hattiesburg, United States
    • Cancer Partners of Nebraska · Lincoln, United States
    • MSK Cancer Center · New York, United States
    • ARENSIA Exploratory Medicine at "MBAL Sveta Sofia" · Sofia, Bulgaria
    • UMHAT "Sv. Ivan Rilski", EAD · Sofia, Bulgaria
    • Hong Kong United Oncology Centre · Hong Kong, China
    • The Chinese University of Hong Kong · Hong Kong, China
    • The University of Hong Kong · Hong Kong, China
    • Gustave Roussy Cancer Campus · Clémont, France
    • Centre Hospitalier Lyon Sud · Lyon, France
    • Groupe Hospitalier Pitie-Salpetriere · Paris, France
    • Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari · Bari, Italy
    • Azienda Socio Sanitaria Territoriale Niguarda (Grande Ospedale Metropolitano Niguarda) · Milan, Italy
    • Fondazione IRCCS Istituto Nazionale dei Tumori · Milan, Italy
    • Fondazione IRCCS Policlinico San Matteo · Pavia, Italy
    • Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im. ks. B. Markiewicza · Brzozów, Poland
    • Uniwersytecki Szpital Kliniczny w Poznaniu, Klinika Onkologii · Poznan, Poland
    • Institutul Oncologic Bucuresti Prof Dr. Al. Trestioreanu with SC Arensia Exploratory Medicine · Bucharest, Romania
    • Institute of Oncology "Ioan Chiricuta" Cluj-Napoca, Arensia Exploratory Medicine · Cluj-Napoca, Romania
    • Centrul de Oncologie Sfantul Nectarie Craiova · Craiova, Romania
    • Seoul National University Bundang Hospital · Seongnam-si, South Korea
    • Seoul National University Hospital · Seoul, South Korea
    • Asan Medical Center · Seoul, South Korea
    • Pratia ES Sirius Barcelona · Barcelona, Spain
    • Hospital Universitario Reina Sofía Córdoba · Córdoba, Spain
    • …and 15 more on the registry record
    Show 1 removed
    • AdventHealth Hematology and Oncology Denver Cypress Hematology and Oncology · Denver, United States
    Eligibility 2 inclusion criteria edited, 3 added; 1 exclusion criterion edited, 4 added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedMale or female gender, age ≥ 18 years at screening.
    • EditedReceiving platinum- and/or gemcitabine-containing chemotherapy regimens on 14- or 21-day treatment cycles.
    • AddedPlatelet count < 85 x 109/L at enrollment.
    • AddedFor Part B, experiencing a chemotherapy delay of ≥ 7 days due to CIT.
    • AddedAt least 2 scheduled chemotherapy cycles of the same treatment regimen as was used prior to enrollment.
    Exclusion criteria
    • AddedWHO Grade ≥ 2 bleeding within 14 days prior to screening.
    • EditedHave arterial/venous thrombosis withinwith anticoagulation not tolerated for at least 6 monthsweeks.
    • RemovedSevere haemorrhage during screening
    • AddedSevere haemorrhage during screening (e.g., gastrointestinal or intracranial hemorrhage) within 28 days prior to enrolment.
    • AddedPrevious treatment with thrombopoietin receptor agonists (TPO-RAs) within 14 days prior to enrolment.
    • AddedPlatelet transfusion within 72 hours prior to enrollment.
    Primary outcomes 5 edited
    What changed in the outcomes
    • EditedPart A: AUC0-tauof hetrombopag in non-Asian participants with CIT, around 6 months.Time frame: around 6 months → around 6 months.
    • EditedPart A: Cmin of hetrombopag in non-Asian participants with CIT, around 6 months.Time frame: around 6 months → around 6 months.
    • EditedPart B: A platelet count of ≥100×109/L within 14 days after initiating the investigational product treatment, around 3 years.Time frame: around 3 years → around 3 years.
    • EditedPart B: No use of any rescue therapy for thrombocytopenia during the treatment period from the initiation of investigational product treatment until Cycle 2 Day 21the end of the primary treatment period, around 3 years.Time frame: around 3 years.
    • EditedPart B: Complete two consecutive on-study chemotherapy cycles (Cycle 1 and Cycle 2) without thrombocytopenia-induced modification of any myelosuppressive agent, around 3 years;.Time frame: around 3 years; → around 3 years.
    Secondary outcomes 4 edited
    What changed in the outcomes
    • EditedProportion of participants achieving platelet count ≥100×109/L without the use of rescue therapy within 14 days after initiating the investigational product treatment, around 3 years;.Time frame: around 3 years; → around 3 years.
    • EditedplateletPlatelet count nadir from Cycle 1 Day 1 until Cycle 2 Day 21the primary treatment period, around 3 years;.Time frame: around 3 years; → around 3 years.
    • EditedProportion of participants free from serious bleeding events, during the treatment period from the initiation of IP treatment until C2D21the primary treatment period, around 3 years;.Time frame: around 3 years; → around 3 years.
    • EditedProportion of participants with neutropenia during the treatment period from the initiation of IP treatment until Cycle 2 Day 21the primary treatment period, around 3 years.Time frame: around 3 years.
    Interventions Changed Hetrombopag Olamine ;Hetrombopag Olamine Placebo→Hetrombopag Olamine; Hetrombopag Olamine Placebo. Arm changed Part B:Hetrombopag Olamine vs Hetrombopag Olamine Placebo→Part B: Hetrombopag Olamine vs Hetrombopag Olamine Placebo
    Contact Study contact changed: j•••@hengrui.com · •••2973→b•••@hengrui.com · •••3900; added j•••@hengrui.com · •••2973. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Mid-Florida Hematology & Oncology Centers, P.A. · Orange City, United StatesContact added (no phone or email listed)
    Title A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (ExCIT)
    + 3 other changes: verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07286032
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Apr 16, 2026
Primary completion
Dec 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Oct 1, 2026

Study contacts

Brian Yu, MD
Contact
brian.yu@hengrui.com
+86 400 828 3900
Junye Xiong, MD
Contact
junye.xiong.jx9@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hetrombopag olamine

Start the discussion